title: Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
abstract: OBJECTIVE
  Consolidation/maintenance therapy in the standard management of ovarian cancer remains controversial, primarily due to the unknown impact of this strategy on overall survival.
  
  
  METHODS
  We examined the survival of a previously reported patient population consecutively treated with either 3 cycles (group A; n = 13 patients) or 12 cycles (group B; n = 13) of single-agent paclitaxel consolidation following 6 cycles of primary induction chemotherapy comprising 6 cycles of carboplatin (AUC = 5), paclitaxel (175 mg/m(2)) and gemcitabine (800 mg/m(2)).
  
  
  RESULTS
  There were no differences in the 2 patient populations regarding known relevant prognostic factors (age, stage, tumor grade). The median progression-free survival was 11 months for group A and 24 months for group B (p = 0.0062). The median overall survival in group A was 38 months and was not reached in group B (p = 0.0019). Current follow-up for these 2 patient groups exceeds 43 months.
  
  
  CONCLUSIONS
  We recognize the important limitations of this study, particularly its sample size and nonrandomized nature. However, these data provide support for the conclusion that paclitaxel 'maintenance/consolidation' therapy may favorably impact overall and progression-free survival in advanced ovarian cancer patients who achieve an excellent response to primary platinum-based chemotherapy.
authors: Gynecologic Oncology Associates, Hoag Cancer Center and Women's Cancer Research Foundation, Newport Beach, CA 92663, USA.
authors: John P
authors: JP
authors: Micha
authors: Bram H
authors: BH
authors: Goldstein
authors: Cheri
authors: C
authors: Graham
authors: Mark A
authors: MA
authors: Rettenmaier
authors: John V
authors: JV
authors: Brown
authors: Jim C
authors: JC
authors: Hu
authors: Maurie
authors: M
authors: Markman
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D017239:Paclitaxel / Q000627:therapeutic use*; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003841:Deoxycytidine; D016190:Carboplatin; D017239:Paclitaxel; D000093542:Gemcitabine